BioMarin Pharmaceutical Inc. is garnering attention for its promising pipeline, which includes several innovative therapies aimed at treating rare genetic diseases.
Analysts suggest that the company's stock could see substantial growth, with predictions indicating a potential 10x increase by the year 2030.
As BioMarin continues to develop its pipeline, investors are closely monitoring its progress and the implications for future stock performance.